1-5 of 5
Jeffrey S. Wiezorek, MD MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 888.
https://doi.org/10.1182/blood.V130.Suppl_1.888.888
Published: 2017
Journal Articles

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Frederick L. Locke, MD, Jason R. Westin, MD, David B. Miklos, MD PhD, Alex F. Herrara, MD, Caron A. Jacobson, MD, Jennifer Lee, John M. Rossi, MS, Adrian Bot, MD PhD, Allen Xue, PhD, Lynn Navale, MS, Jeff S. Aycock, Jeffrey S. Wiezorek, MD MS, Zachary J. Roberts, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2826.
https://doi.org/10.1182/blood.V130.Suppl_1.2826.2826
Published: 2017
Journal Articles

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Marika Sherman, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD, David B. Miklos, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1547.
https://doi.org/10.1182/blood.V130.Suppl_1.1547.1547
Published: 2017
Journal Articles

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, David B. Miklos, MD PhD, Eric D. Jacobsen, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 578.
https://doi.org/10.1182/blood.V130.Suppl_1.578.578
Published: 2017
Journal Articles

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric W. Van Den Neste, MD PhD, Umar Farooq, MD, Lynn Navale, MS, William Y. Go, MD PhD, Jeffrey S. Wiezorek, MD MS, Christian Gisselbrecht
Journal: Blood
Blood (2017) 130 (Supplement 1): 579.
https://doi.org/10.1182/blood.V130.Suppl_1.579.579
Published: 2017